Company: BDRX
Filing Date: 2025-12-11
Form Type: F-1/A
Source: 0001214659-25-017944
Chunk: 44

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-11
Form: F-1/A
Chunk 44
---
| Simon Turton (4)                                           |     |              |  14,402,765 |     |          | * |
| Sijmen de Vries (5)                                        |     |              |  14,400,000 |     |          | * |
| Directors and senior management as a group (5 persons) (6) |     |              | 109,635,140 |     |          | * |

________________

| * | Represents beneficial ownership of less than one percent. |

| 30 |

| (1) | Shares owned by Ms. Merchant are Ordinary                                                
 Shares subject to outstanding stock options which are exercisable at December 1, 2025 or 
 will become exercisable within 60 days after such date.                                  |

| (2) | Shares owned by Dr. Parker are Ordinary                                                  
 Shares subject to outstanding stock options which are exercisable at December 1, 2025 or 
 will become exercisable within 60 days after such date.                                  |

| (3) | Shares owned by Mr. Stamp are Ordinary                                                   
 Shares subject to outstanding stock options which are exercisable at December 1, 2025 or 
 will become exercisable within 60 days after such date.                                  |

| (4) | Shares owned by Dr. Turton include                                                       
 14,400,000 Ordinary Shares subject to outstanding stock options which are exercisable at 
 December 1, 2025 or will become exercisable within 60 days after such date.              |

| (5) | Shares owned by Dr. de Vries are Ordinary                                                
 Shares subject to outstanding stock options which are exercisable at December 1, 2025 or 
 will become exercisable within 60 days after such date.                                  |

| (6) | Shares owned by all directors and                                                             
 senior management as a group include 109,632,375 Ordinary Shares subject to outstanding stock 
 options, which are exercisable at December 1, 2025 or will become exercisable within 60 days  
 after such date.                                                                              |

As
of December 1, 2025, approximately 0.0006% of our outstanding Ordinary Shares was held by registered shareholders with addresses in the
United Kingdom, and we had 185 holders of record in the United Kingdom (in each case, excluding shares held by the custodian under our
depositary agreement with JPMorgan Chase Bank, N.A.). As of December 1, 2025, JPMorgan